The trademark application TRANSLATIONAL INDEX was filed by VeriSIM Life Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on December 7, 2023, and it was registered by office on March 15, 2024 without any oppositions.
The application was filed in English (German was selected as the second language).
Change of name and professional address of the trademark registration was recorded on January 3, 2024.
Goods And Services
The mark was filed in class 42 with following description of goods:
Software as a service (SAAS) services featuring software for modeling, rating, scoring and reporting on the conducting of simulations and predictions of properties of drugs or chemicals or vaccines including absorption, release rate, bioavailability, pharmacokinetics and pharmacodynamics, safety, toxicology, and efficacy profiles, routes of administration, and dose optimization
Software as a service (SAAS) services featuring software that allows for the simulation, prediction, rating, scoring, and reporting of drug-to-drug interactions
Software as a service (SAAS) services featuring software for the simulation, prediction, rating, scoring, and reporting of drug or vaccines or chemical effects on animals and virtual animal or patient populations
Software as a service (SAAS) services featuring software which allows researchers to adjust pharmacodynamic models to observed data and to then use the resulting fitted models to simulate, predict, rate, score, and report on pharmacodynamic changes due to changes in routes of administration, dose, dosage form, and dosing regimen of a drug or chemical or vaccine
Software as a service (SAAS) services featuring software which allow for the prediction, rating, scoring, and reporting of absorption and systemic distribution/elimination for large molecules
Software as a service (SAAS) services featuring software that incorporates artificial intelligence and machine learning to simulate, predict, rate, score, and report on the clinical efficacy of new drugs or chemicals or vaccines before human trials and accelerate pharmaceutical drug or vaccine development and regulatory approval.